Comparison of the allele frequencies of MS patients to those of the controls was performed using a 2 x 2 contingency Chi square.'0 The expected phenotype frequencies were calculated by applying the Hardy-Weinberg distribution (a2 + 2ab + b2 = 1) to the sum of the cases and controls. Odds ratio with 95% confidence intervals were calculated for the three phenotypes in cases versus controls.
Methods

Diagnosis
Only white MS patients who were diagnosed as clinically definite7 or laboratory supported probable MS8 were included in this study. All of the patients in this study were selected at random from the MS clinic in London, Ontario.9 The control subjects were white, over the age of twenty five and had negative neurological histories. No participants in this study were related.
The ratio of males to females in the MS patient group was 1:1 -8, which is the same ratio observed for the entire clinic population of 1400. Comparison of the allele frequencies of MS patients to those of the controls was performed using a 2 x 2 contingency Chi square.'0 The expected phenotype frequencies were calculated by applying the Hardy-Weinberg distribution (a2 + 2ab + b2 = 1) to the sum of the cases and controls. Odds ratio with 95% confidence intervals were calculated for the three phenotypes in cases versus controls.
Results
A total of 200 individuals were typed for C3 alleles, of whom two (one member of the control group and one of the MS patients) had an uncommon allele; subsequently these samples were not included in the study. The results of the typing are shown in table 1. The frequency of C3F allele was 0 1957 and 0-2210, while the frequency of C3s allele was 0-8043 and 0-7790 in the control and MS populations respectively. The distribution of the three common phenotypes (SS, FS, FF) within the control group compared with the MS patients was not significantly different (Chi square = 2-782; 2 df; 0-10 < P < 0-25). Assuming that the C3 system is in a Hardy-Weinberg equilibrium, good agreement was found between observed and expected values (Chi square = 0-150; 1 df; 0 50 < P < 0-75 The results given in the tables suggest that there is no association between any C3 allele and MS. An earlier report, however, had suggested a modest association between MS and C3F.6 There are differences between these two studies in the size ofthe patient and control groups. Jans and Sorensen typed 60 patients and 1066 blood donors (controls). In this study 129 patients and 69 neurologically normal controls were typed and no difference in allele frequency was found. Similarly there was no difference between the MS patients in this study and the larger control group of Jans and Sorensen (Chi square = 5-416; p > 0-05). Finally, the allele frequencies in the London, Ontario MS population (100% white) of 0 7790 and 0-2210 for C3s and C3F respectively, are extremely close to the frequencies 0-77 and 0-22 reported for the white population.'5 The reason for the discrepancy between the studies is unclear but it may be due to the smaller patient group of the earlier study or it may be due to ethnic variation within the control group. Because the gene frequency of C3F is approximately 20%, homozygotes for the fast allele of C3 would represent only 4% of the population, thus requiring a relatively large patient sample size for definitive results.
Our results suggest that there is no association between MS and any particular allele of C3. It is possible tha-t the reported association reflects yet another population association secondary to differential MS patient and control stratification.
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